PTPI logoPTPI
Petros Pharmaceuticals Inc

8,211
Loading...
Loading...
News
all
press releases
Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers
Petros Pharmaceuticals hit an all-time low after a 1-for-25 reverse stock split, drawing bullish retail chatter even as delisting risks and mounting losses weighed on the stock.
Stocktwits·5mo ago
News Placeholder
More News
News Placeholder
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI Research Report) yesterday. The company's shares closed ye...
TipRanks Financial Blog·1y ago
News Placeholder
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the...
Benzinga·1y ago
News Placeholder
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...
InvestorPlace·1y ago
News Placeholder
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56...
Accesswire·1y ago
News Placeholder
Petros Pharmaceuticals (NASDAQ:PTPI) & Liberty Health Sciences (OTCMKTS:LHSIF) Critical Review
Liberty Health Sciences (OTCMKTS:LHSIF - Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will...
Zolmax·1y ago
News Placeholder
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC...
Accesswire·1y ago
News Placeholder
Petros Pharmaceuticals enters AI-licensing agreement with software provider
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc...
Accesswire·2y ago
News Placeholder
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc...
Accesswire·2y ago

Latest PTPI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.